Designing transcription factor architectures for drug discovery

Pilar Blancafort, David Segal, Carlos F. Barbas

Research output: Contribution to journalArticle

136 Citations (Scopus)

Abstract

Recent advances in the design, selection, and engineering of DNA binding proteins have led to the emerging field of designer transcription factors (TFs). Modular DNA-binding protein domains can be assembled to recognize a given sequence of a DNA in a regulatory region of a targeted gene. TFs can be readily prepared by linking the DNA-binding protein to a variety of effector domains that mediate transcriptional activation or repression. Furthermore, the interaction between the TF and the genomic DNA can be regulated by several approaches, including chemical regulation by a variety of small molecules. Genome-wide single target specificity has been demonstrated using arrays of sequence-specific zinc finger (ZF) domains, polydactyl proteins. Any laboratory today can easily construct polydactyl ZF proteins by linkage of predefined ZF units that recognize specific triplets of DNA. The potential of this technology to alter the transcription of specific genes, to discover new genes, and to induce phenotypes in cells and organisms is now being applied in the areas of molecular therapeutics, pharmacology, biotechnology, and functional genomics.

Original languageEnglish (US)
Pages (from-to)1361-1371
Number of pages11
JournalMolecular Pharmacology
Volume66
Issue number6
DOIs
StatePublished - Dec 2004
Externally publishedYes

Fingerprint

Zinc Fingers
DNA-Binding Proteins
Drug Discovery
Transcription Factors
Genes
Nucleic Acid Regulatory Sequences
DNA
Biotechnology
Genomics
Transcriptional Activation
Genome
Pharmacology
Technology
Phenotype
Proteins
Protein Domains
Therapeutics

ASJC Scopus subject areas

  • Pharmacology

Cite this

Designing transcription factor architectures for drug discovery. / Blancafort, Pilar; Segal, David; Barbas, Carlos F.

In: Molecular Pharmacology, Vol. 66, No. 6, 12.2004, p. 1361-1371.

Research output: Contribution to journalArticle

Blancafort, Pilar ; Segal, David ; Barbas, Carlos F. / Designing transcription factor architectures for drug discovery. In: Molecular Pharmacology. 2004 ; Vol. 66, No. 6. pp. 1361-1371.
@article{cdfb2907f23e48caabc51af4fac14a3c,
title = "Designing transcription factor architectures for drug discovery",
abstract = "Recent advances in the design, selection, and engineering of DNA binding proteins have led to the emerging field of designer transcription factors (TFs). Modular DNA-binding protein domains can be assembled to recognize a given sequence of a DNA in a regulatory region of a targeted gene. TFs can be readily prepared by linking the DNA-binding protein to a variety of effector domains that mediate transcriptional activation or repression. Furthermore, the interaction between the TF and the genomic DNA can be regulated by several approaches, including chemical regulation by a variety of small molecules. Genome-wide single target specificity has been demonstrated using arrays of sequence-specific zinc finger (ZF) domains, polydactyl proteins. Any laboratory today can easily construct polydactyl ZF proteins by linkage of predefined ZF units that recognize specific triplets of DNA. The potential of this technology to alter the transcription of specific genes, to discover new genes, and to induce phenotypes in cells and organisms is now being applied in the areas of molecular therapeutics, pharmacology, biotechnology, and functional genomics.",
author = "Pilar Blancafort and David Segal and Barbas, {Carlos F.}",
year = "2004",
month = "12",
doi = "10.1124/mol.104.002758",
language = "English (US)",
volume = "66",
pages = "1361--1371",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "6",

}

TY - JOUR

T1 - Designing transcription factor architectures for drug discovery

AU - Blancafort, Pilar

AU - Segal, David

AU - Barbas, Carlos F.

PY - 2004/12

Y1 - 2004/12

N2 - Recent advances in the design, selection, and engineering of DNA binding proteins have led to the emerging field of designer transcription factors (TFs). Modular DNA-binding protein domains can be assembled to recognize a given sequence of a DNA in a regulatory region of a targeted gene. TFs can be readily prepared by linking the DNA-binding protein to a variety of effector domains that mediate transcriptional activation or repression. Furthermore, the interaction between the TF and the genomic DNA can be regulated by several approaches, including chemical regulation by a variety of small molecules. Genome-wide single target specificity has been demonstrated using arrays of sequence-specific zinc finger (ZF) domains, polydactyl proteins. Any laboratory today can easily construct polydactyl ZF proteins by linkage of predefined ZF units that recognize specific triplets of DNA. The potential of this technology to alter the transcription of specific genes, to discover new genes, and to induce phenotypes in cells and organisms is now being applied in the areas of molecular therapeutics, pharmacology, biotechnology, and functional genomics.

AB - Recent advances in the design, selection, and engineering of DNA binding proteins have led to the emerging field of designer transcription factors (TFs). Modular DNA-binding protein domains can be assembled to recognize a given sequence of a DNA in a regulatory region of a targeted gene. TFs can be readily prepared by linking the DNA-binding protein to a variety of effector domains that mediate transcriptional activation or repression. Furthermore, the interaction between the TF and the genomic DNA can be regulated by several approaches, including chemical regulation by a variety of small molecules. Genome-wide single target specificity has been demonstrated using arrays of sequence-specific zinc finger (ZF) domains, polydactyl proteins. Any laboratory today can easily construct polydactyl ZF proteins by linkage of predefined ZF units that recognize specific triplets of DNA. The potential of this technology to alter the transcription of specific genes, to discover new genes, and to induce phenotypes in cells and organisms is now being applied in the areas of molecular therapeutics, pharmacology, biotechnology, and functional genomics.

UR - http://www.scopus.com/inward/record.url?scp=9444230573&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9444230573&partnerID=8YFLogxK

U2 - 10.1124/mol.104.002758

DO - 10.1124/mol.104.002758

M3 - Article

C2 - 15340042

AN - SCOPUS:9444230573

VL - 66

SP - 1361

EP - 1371

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 6

ER -